Medtronic plc, the global leader in medical technology, today announced the launch of a new ECMO system called VitalFlow™, which is a configurable one-system ECMO solution, built on simplicity and performance. The VitalFlow™ ECMO System bridges the gap between bedside care and intra-hospital transport, offering physicians and clinicians an easier, smarter ECMO experience..

全球医疗技术领导者美敦力公司（Medtronic plc）今天宣布推出一种名为VitalFlow™的新型ECMO系统，这是一种基于简单性和性能的可配置单系统ECMO解决方案。VitalFlow™ECMO系统弥合了床边护理和院内运输之间的差距，为医生和临床医生提供了更简单，更智能的ECMO体验。。

The VitalFlow™ technology is the most innovative technology to-date from the Medtronic acquisition of MC3 Cardiopulmonary, which closed in March 2024. The acquisition marked the culmination of an eight-year partnership and distribution agreement with the Medtronic Cardiac Surgery business resulting in the introduction of seven new ECMO products in seven years.

VitalFlow™技术是美敦力收购MC3心肺公司以来最具创新性的技术，该公司于2024年3月关闭。此次收购标志着与美敦力心脏外科业务部门签订了为期八年的合作和分销协议，从而在七年内推出了七种新的ECMO产品。

Prior to the acquisition, MC3 Cardiopulmonary consistently developed and manufactured differentiated, high-quality ECMO products, which were exclusively distributed by Medtronic. These products, including catheters and oxygenators, are distinguished by their ability to simplify therapy and enhance ease of use.

在收购之前，MC3心肺一直在开发和制造差异化的高质量ECMO产品，这些产品由美敦力独家经销。这些产品，包括导管和氧合器，以其简化治疗和提高易用性的能力而闻名。

Additionally, the partnership has reliably supplied these long-term indicated products throughout the COVID pandemic and beyond..

此外，该合作伙伴关系在整个新型冠状病毒大流行期间及以后可靠地提供了这些长期指示产品。。

'The launch of this technology further underscores Medtronic's unwavering dedication to developing life-restoring medical devices that address both acute and chronic cardiopulmonary clinical needs, and demonstrates our sustained commitment to this vital field,' said Karim Bandali, Ph.D., president of the Cardiac Surgery business within the Cardiovascular portfolio at Medtronic.

美敦力心血管投资组合心脏外科业务总裁卡里姆·班达利（KarimBandali）博士说：“这项技术的推出进一步突显了美敦力坚定不移地致力于开发能够满足急性和慢性心肺临床需求的恢复生命的医疗设备，并证明了我们对这一重要领域的持续承诺。”。

'This announcement builds on our recent acquisitions, including a Viant Medical contract manufacturing site and the Penditure™ Left Atrial Appendage Exclusion System. Clinicians can continue to expect a global cadence of bold and unique innovations, focused on addressing diverse clinician needs while enhancing our ability to meet the needs of all cardiac surgery patients.”.

“这项宣布建立在我们最近收购的基础上，包括Viant医疗合同制造网站和Penditure™左心耳排除系统。临床医生可以继续期待大胆和独特创新的全球节奏，专注于满足不同的临床医生需求，同时提高我们满足所有心脏手术患者需求的能力。”。

These latest acquisitions enable Medtronic to offer the most robust Cardiac Surgery portfolio available today. As the only business that serves the whole heart care team of cardiac surgeons and perfusionists, Medtronic is committed to innovating in heart valves, surgical ablation, left atrial appendage management (LAAM), revascularization, perfusion, cannulation technologies, and ECMO therapies to advance treatment options, providing distinct benefits to physicians and clinicians, enabling them to focus on the holistic lifetime management of patients..

这些最新收购使美敦力能够提供当今最强大的心脏手术组合。作为唯一一家为心脏外科医生和灌注医师的整个心脏护理团队提供服务的企业，美敦力致力于在心脏瓣膜、手术消融、左心耳管理（LAAM）、血运重建、灌注、插管技术和ECMO治疗方面进行创新，以推进治疗选择，为医生和临床医生提供独特的利益，使他们能够专注于患者的整体终身管理。。

The VitalFlow system brings a critical solution for ECMO

VitalFlow系统为ECMO带来了关键的解决方案

The user-friendly VitalFlow system features a large, intuitive touch screen that centralizes real-time performance data, offers configurability, and is built for long-term performance incorporating the proven Medtronic Nautilus™ ECMO oxygenator design.

用户友好的VitalFlow系统具有一个大而直观的触摸屏，可集中实时性能数据，提供可配置性，并结合经验证的美敦力Nautilus™ECMO氧合器设计，为长期性能而构建。

“In gathering feedback from hundreds of clinicians with diverse ECMO specialties, we were able to design the VitalFlow system to address the most pressing unmet needs of simplicity, configurability and performance in an ECMO system,” said Bandali. “The simplicity of the VitalFlow system allows multiple users with varying levels of comfort to serve patients confidently and efficiently.

班达利说：“通过收集数百名具有不同ECMO专业的临床医生的反馈，我们能够设计VitalFlow系统，以解决ECMO系统中最迫切的未满足的简单性，可配置性和性能需求。”。“VitalFlow系统的简单性允许多个用户以不同程度的舒适度自信高效地为患者服务。

It is easily portable from various departments within the hospital setting, with durable and reliable performance.”.

它很容易从医院环境中的各个部门携带，性能耐用可靠。”。

The VitalFlow system and other Medtronic ECMO technologies will be featured at the upcoming 35th Annual Conference of the Extracorporeal Life Support Organization (ELSO) from September 29 - October 1 in Detroit where Medtronic will also hold two ECMO Workshops to facilitate hands-on engagement and learnings for the company’s ECMO technologies.

VitalFlow系统和其他美敦力ECMO技术将于9月29日至10月1日在底特律举行的体外生命支持组织（ELSO）第35届年会上展出，美敦力还将在会上举办两次ECMO研讨会，以促进公司ECMO技术的实际参与和学习。

The workshops will focus on VitalFlow system simulations, and cannulation with the Crescent™ RA pediatric cannula, the Bio Medicus™ LS cannula, and the Crescent™ cannula..

研讨会将重点讨论VitalFlow系统模拟，以及使用Crescent™RA儿科插管、Bio-Medicus™LS插管和Crescent™插管进行插管。。

“Clinicians in the ECMO space have evolving needs,” said Pieter Kappetein, Ph.D., M.D., chief medical officer, Cardiac Surgery, Medtronic. “With patients' diseases becoming more complex, there is a growing demand for innovative solutions and comprehensive commitments across multiple disease states. Clinicians expect more from Medtronic and we are uniquely positioned to meet these needs to advance treatment options to better serve their patients.”.

美敦力心脏外科首席医疗官PieterKappetin博士说：“ECMO领域的临床医生有不断发展的需求。”。“随着患者的疾病变得越来越复杂，对多种疾病状态的创新解决方案和全面承诺的需求越来越大。临床医生对美敦力的期望越来越高，我们拥有独特的优势来满足这些需求，以推进治疗选择，更好地为患者服务。”。

About ECMO

关于ECMO

ECMO uses a pump and oxygenator outside of the body to take over the work of the heart and lungs to restore health and extend life to critically ill patients who might otherwise expire. ECMO is most often used for life-threatening heart or lung failure to allow the heart and/or lung to rest and heal.

ECMO使用体外的泵和氧合器来接管心脏和肺部的工作，以恢复健康并延长可能会过期的重症患者的寿命。ECMO最常用于危及生命的心脏或肺衰竭，以使心脏和/或肺休息和愈合。

It’s also used as a bridge option to heart or lung transplantation or to further treatment such as heart assist device or left ventricular assist device (LVAD)..

它也被用作心脏或肺移植或进一步治疗（如心脏辅助装置或左心室辅助装置（LVAD））的桥梁选择。。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。总部位于爱尔兰戈尔韦的美敦力公司是全球领先的医疗保健技术公司，通过寻找和寻找解决方案，大胆应对人类面临的最具挑战性的健康问题。我们的使命是减轻痛苦，恢复健康，延长生命，我们将150多个国家的95000多名充满激情的全球团队团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们丰富的知识、永不满足的好奇心以及帮助所有需要帮助的人的愿望，我们提供了创新技术，每秒钟、每小时、每天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn..

随着我们增强洞察力驱动的护理、以人为本的体验以及为我们的世界带来更好的结果，对我们的期望会更高。在我们所做的每件事中，我们都在创造非凡。有关美敦力的更多信息，请访问www.Medtronic.com并在LinkedIn上关注美敦力。。